B
Bull
Bull · 25%BGLC
$7.07
Szenariopreis
$1.460
-0.029 (-2.01%)Zum Schluss
Loading chart…
- High
- 1.500
- Open
- 1.500
- VWAP
- 1.49
- Vol
- 1.08K
- Mkt Cap
- 8.14M
- Low
- 1.500
- Amount
- 1.61K
- EV/EBITDA, TTM
- 0.00
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business.
AI analysis of BioNexus Gene Lab Corp (BGLC)
buyBioNexus Gene Lab Corp (BGLC) is a good buy right now due to its recent stock surge of 82.96% after a strategic partnership announcement, indicating strong market interest. Additionally, the stock's current price of 1.55 is significantly below its 200-day moving average of 2.605, suggesting potential for recovery. However, the company has a negative net income of -286451 in the latest quarter, which remains a key risk.
Bewertungskennzahlen
The current forward P/E ratio for BioNexus Gene Lab Corp (BGLC) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for BGLC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
7.505-29NewsfilterBioNexus Participates in China-Malaysia Economic Cooperation Forum
- 4.502-23Newsfilter
BioNexus Restructures Subsidiary Governance Framework
- 2.001-28Newsfilter
BioNexus Launches VitaGuard™ Deployment Phase for Oncology Monitoring
7.512-02GlobenewswireBioNexus Gene Lab Corp. Secures $500 Million Equity Purchase Agreement with ARC Group
- 7.510-20Newsfilter
BioNexus Gene Lab Corp Enters Strategic Partnership Agreement with BirchBioMed Inc.
BGLC FAQ — answered by Alphio AI
BioNexus Gene Lab Corp. is a biotechnology company specializing in precision diagnostics and specialty chemical solutions. The Company, through its wholly owned subsidiary Chemrex Corporation Sdn. Bhd., focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. Its segments include Trading of industrial chemicals, Provision for genomic screening services, and Investment holding. The Provision for genomic screening services segment includes commercializing proprietary blood-based diagnostic test for early disease detection. Its subsidiary MRNA Scientific Sdn. Bhd owns algorithm software, technology, and know-how related to the detection of common diseases through blood analysis which it uses in its business. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
BioNexus Gene Lab Corp (BGLC) is a good buy right now due to its recent stock surge of 82.96% after a strategic partnership announcement, indicating strong market interest. Additionally, the stock's current price of 1.55 is significantly below its 200-day moving average of 2.605, suggesting potential for recovery. However, the company has a negative net income of -286451 in the latest quarter, which remains a key risk.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.